ANALYSIS OF DASATINIB AND IMATINIB 5-YEAR EFFICACY AND SAFETY BASED ON BASELINE COMORBIDITY AND AGE IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) IN DASISION

被引：0
|
作者：
Saglio, G. [1 ]
Cortes, J. E. [2 ]
Hochhaus, A. [3 ]
Shah, N. P. [4 ]
Atallah, E. L. [5 ,6 ]
Abaskharoun, M. [7 ]
Li, L. [7 ]
Mauro, M. J. [8 ]
机构：
[1] Univ Turin, Turin, Italy
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Klinikum Jena, Jena, Germany
[4] Univ Calif San Francisco, Sch Med, San Francisco, CA USA
[5] Froedtert, Milwaukee, WI USA
[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[7] Bristol Myers Squibb Co, Princeton, NJ USA
[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1060
引用
收藏
页码：436 / 437
页数：2
相关论文
共 50 条
  • [31] Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION.
    Shah, Neil P.
    Saglio, Giuseppe
    Hochhaus, Andreas
    Bilmes, Robyn
    Li, Li
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] CONTINUED SUPERIORITY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND BEYOND 1 YEAR
    Hochhaus, A.
    Lobo, C.
    Pasquini, R.
    Clark, R.
    Kim, D. W.
    Issaragrisil, S.
    le Coutre, P.
    Reiffers, J.
    Kantarjian, H.
    Saglio, G.
    Edrich, P.
    Hoenekopp, A.
    Gallagher, N.
    Larson, R.
    Hughes, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 459 - 459
  • [33] ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
    Hughes, Timothy P.
    Hochhaus, Andreas
    Saglio, Giuseppe
    Kim, Dong-Wook
    Jootar, Saengsuree
    le Coutre, Philipp D.
    Reiffers, Josy
    Pasquini, Ricardo
    Lobo, Clarisse
    Clark, Richard E.
    Gallagher, Neil J.
    Hoenekopp, Albert
    Haque, Ariful
    Larson, Richard A.
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 94 - 95
  • [34] Evaluating the Role of Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP)
    Naqvi, Kiran
    Cortes, Jorge E.
    Skinner, Jeffrey
    Jabbour, Elias J.
    Pemmaraju, Naveen
    Bose, Prithviraj
    Thompson, Philip A.
    Borthakur, Gautam
    Estrov, Zeev
    Kantarjian, Hagop M.
    BLOOD, 2017, 130
  • [35] Opportunistic Infections Are Uncommon with Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
    Al-Ameri, Ali
    Kantarjian, Hagop
    Borthakur, Gautam
    Bahceci, Erkut
    Szatrowski, Ted
    Damokosh, Andrew
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 459 - 459
  • [36] Molecular Responses to Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Michor, Franziska
    Olshen, Adam
    Gonen, Mithat
    Jones, Dan
    Rios, Mary Beth
    O'Brien, Susan
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 1114 - 1115
  • [37] DASATINIB EFFICACY AFTER IMATINIB FAILURE BY DOSING SCHEDULE AND BASELINE BCR-ABL MUTATION STATUS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
    Hochhaus, A.
    Mueller, M. C.
    Cortes, J.
    Kim, D. W.
    Matloub, Y.
    Ploughman, L.
    Hughes, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 371 - 372
  • [38] Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update
    Larson, Richard A.
    Hochhaus, Andreas
    Saglio, Giuseppe
    Kim, Dong-Wook
    Jootar, Saengsuree
    Le Coutre, Philipp D.
    Reiffers, Josy
    Pasquini, Ricardo
    Goldberg, Stuart L.
    Clark, Richard E.
    Kemp, Charisse N.
    Fan, Xiaolin
    Menssen, Hans D.
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in ehronic phase (CML-CP): ENESTnd beyond one year
    Larson, R. A.
    le Coutre, P. D.
    Reiffers, J.
    Hughes, T. P.
    Saglio, G.
    Edrich, P.
    Hoenekopp, A.
    Gallagher, N. J.
    Kantarjian, H.
    Hochhaus, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase (CML-CP)
    Kantarjian, Hagop M.
    Druker, Brian J.
    Guilhot, Francois
    Cortes, Jorge
    O'Brien, Stephen G.
    Krahnke, Tillmann
    Larson, Richard A.
    BLOOD, 2007, 110 (11) : 317A - 317A
12345